Literature DB >> 25026101

Disseminated Kaposi's sarcoma in patients with HIV infection correlates to high serum levels of IL-10.

Paula Renata Lima Machado1, Kleber Juvenal Silva Farias, Julieta Genre, Carlo José Freire Oliveira, Paulo Marcos Matta Guedes, Benedito Antônio Lopes da Fonseca.   

Abstract

Human herpesvirus 8 (HHV-8) is the etiologic agent of all Kaposi's sarcoma (KS), the outcome of which is associated with immuno-dysregulation, resulting in the abnormal production of inflammatory cytokines and chemokines. We quantified by enzyme-linked immunosorbent assay serum levels of interleukin (IL)-10, IL-17, interferon (IFN)-γ, and tumor necrosis factor (TNF)-α from patients with KS-AIDS, classic KS, and human immunodeficiency virus (HIV) without KS. A correlation between HHV-8 molecular detection and cytokine production was also performed. We observed that IL-10 production was higher in patients with KS-AIDS when compared to those with classic KS or HIV. However, no significant differences were seen for IFN-γ, TNF-α, or IL-17 production between studied groups. When patients with KS-AIDS were analyzed according to lesion topography, IL-10 levels were higher in patients with disseminated disease than those observed in patients with only cutaneous lesions or cutaneous and digestive and/or respiratory tract lesions. Finally, patients with KS-AIDS that presented viral DNA for HHV-8 in serum showed a higher production of IL-10 when compared with those patients with a negative result for nested polymerase chain reaction for the virus. The results presented here are the first to demonstrate that there exists a stratification of patients with KS-AIDS according to lesion topography where IL-10 levels are higher in those individuals with disseminated disease than those with only localized lesions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25026101      PMCID: PMC4150374          DOI: 10.1089/vim.2013.0134

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  22 in total

1.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.

Authors:  Mark N Polizzotto; Thomas S Uldrick; Victoria Wang; Karen Aleman; Kathleen M Wyvill; Vickie Marshall; Stefania Pittaluga; Deirdre O'Mahony; Denise Whitby; Giovanna Tosato; Seth M Steinberg; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

2.  The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant.

Authors:  S Sozzani; W Luini; G Bianchi; P Allavena; T N Wells; M Napolitano; G Bernardini; A Vecchi; D D'Ambrosio; D Mazzeo; F Sinigaglia; A Santoni; E Maggi; S Romagnani; A Mantovani
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

3.  Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery.

Authors:  Gennaro Galizia; Michele Orditura; Ciro Romano; Eva Lieto; Paolo Castellano; Luigi Pelosio; Vincenzo Imperatore; Giuseppe Catalano; Carlo Pignatelli; Ferdinando De Vita
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

4.  Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer.

Authors:  A Jebreel; D Mistry; D Loke; G Dunn; V Hough; K Oliver; N Stafford; J Greenman
Journal:  J Laryngol Otol       Date:  2006-08-15       Impact factor: 1.469

5.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients.

Authors:  E Oksenhendler; G Carcelain; Y Aoki; E Boulanger; A Maillard; J P Clauvel; F Agbalika
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.

Authors:  E Cesarman; Y Chang; P S Moore; J W Said; D M Knowles
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

Review 7.  Chemokines and Kaposi's sarcoma.

Authors:  Kristian K Jensen; Sergio A Lira
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

8.  Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.

Authors:  L Kozłowski; I Zakrzewska; P Tokajuk; M Z Wojtukiewicz
Journal:  Rocz Akad Med Bialymst       Date:  2003

9.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

10.  Interleukin 10 production by human melanoma.

Authors:  T Sato; P McCue; K Masuoka; S Salwen; E C Lattime; M J Mastrangelo; D Berd
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

View more
  4 in total

Review 1.  Cells of the Innate and Adaptive Immune Systems in Kaposi's Sarcoma.

Authors:  Owen Ngalamika; Sody Munsaka
Journal:  J Immunol Res       Date:  2020-11-21       Impact factor: 4.818

2.  Kaposi's Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies.

Authors:  Egidio Brocca-Cofano; Cecilia Sgadari; Orietta Picconi; Clelia Palladino; Antonella Caputo; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

3.  Kaposi's sarcoma-associated herpesvirus seropositivity is associated with parasite infections in Ugandan fishing communities on Lake Victoria islands.

Authors:  Angela Nalwoga; Emily L Webb; Belinda Chihota; Wendell Miley; Bridgious Walusimbi; Jacent Nassuuna; Richard E Sanya; Gyaviira Nkurunungi; Nazzarena Labo; Alison M Elliott; Stephen Cose; Denise Whitby; Robert Newton
Journal:  PLoS Negl Trop Dis       Date:  2019-10-16

Review 4.  Cytokine-Targeted Therapeutics for KSHV-Associated Disease.

Authors:  Nedaa Alomari; Jennifer Totonchy
Journal:  Viruses       Date:  2020-09-28       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.